Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 4/20 | 0.33 |
| ▸ | PEPD | P12955 | 2/20 | 0.32 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 3/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201656 | 0.89 | CASP3 (0.36) | CASP3ACELCKKMT2A | |
| SCHEMBL10201316 | 0.82 | FKBP1A (0.41) | FKBP1APOLBCASP3ACEPEPD | |
| SCHEMBL10201668 | 0.81 | FKBP1A (0.38) | FKBP1APOLBCASP3ACEPEPD | |
| SCHEMBL10201690 | 0.77 | NPC1 (0.41) | POLBCASP3KMT2A | |
| SCHEMBL13140078 | 0.77 | FKBP1A (0.35) | FKBP1APOLBCASP3ACEPEPD | |
| SCHEMBL13815136 | 0.77 | ACE (0.35) | ACEMME | |
| SCHEMBL10248039 | 0.75 | CASP1 (0.56) | LCK | |
| SCHEMBL10199580 | 0.75 | CASP1 (0.56) | LCK | |
| SCHEMBL10248534 | 0.74 | ACE (0.41) | FKBP1ACASP3ACEMMEKMT2A | |
| SCHEMBL7326405 | 0.73 | POLB (0.36) | FKBP1APOLBCASP3ACEPEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | FKBP1A 685/4885POLB 508/4885CASP3 85/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | FKBP1A 685/4885POLB 508/4885CASP3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.